Jessica Hergert


CAR T-Cell Therapy Recipients May Require Specialized COVID-19 Vaccine Strategies

November 03, 2021

CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.

New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast Cancer

October 23, 2021

The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.

Salvage Regorafenib Emphasizes Need for Nuanced Treatment Selection in Metastatic CRC

October 09, 2021

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.